103例患者卡瑞利珠单抗超适应证用药的合理性分析  

Rationality Analysis of Off-Label Indications Use of Carrilizumab in 103 Patients

作　　者：戴丽[1] 王凤玲[1] 邢海燕[1] 汪星辉[1] 孟祥云[1] DAI Li;WANG Fengling;XING Haiyan;WANG Xinghui;MENG Xiangyun(Dept.of Pharmacy,the Second People’s Hospital of Hefei,Hefei 230011,China)

机构地区：[1]合肥市第二人民医院药学部,合肥230011

出　　处：《中国医院用药评价与分析》2023年第8期1008-1010,1015,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：安徽省合肥市医学重点学科建设项目(No.合卫科教〔2019〕160号)。

摘　　要：目的:探讨该院卡瑞利珠单抗超适应证用药的合理性,为临床用药提供参考和依据。方法:选取2019年7月至2022年3月该院使用卡瑞利珠单抗的患者资料,对患者的性别、年龄、肿瘤类型和临床诊断等进行统计分析。依据该院卡瑞利珠单抗超适应证用药评价标准,对选取的病例资料进行用药合理性评价与分析。结果:共纳入103例使用卡瑞利珠单抗的患者,其中47例存在超适应证用药,超适应证用药率为45.63%。47例存在超适应证用药的患者中,25.53%的患者(12例)缺乏循证医学证据,如使用卡瑞利珠单抗治疗肝胆管细胞癌、纤维组织细胞瘤和前列腺癌等。结论:该院卡瑞利珠单抗超适应证用药率较高,循证医学证据级别较低。应加强对卡瑞利珠单抗超适应证用药的管理,限制无循证医学证据的超适应证用药行为,保障患者用药安全。OBJECTIVE:To probe into the rationality of off-label indications use of carrilizumab,so as to provide reference and basis for clinical drug use.METHODS:Data of inpatients using carrelizumab in the hospital from Jul.2019 to Mar.2022 were extracted,and the gender,age,tumor type and clinical diagnosis of patients were statistically analyzed.According to evaluation criteria for off-label indications of camrelizumab in the hospital,the rationality of the extracted cases was evaluated and analyzed.RESULTS:A total of 103 patients treated with carrelizumab were included,among which 47 cases were off-label indications,with the rate of 45.63%.Of the 47 patients with off-label indications,25.53%(12 cases)lacked evidence-based medical evidence,such as the use of carrilizumab in the treatment of hepatobiliary cell carcinoma,fibrous histiocytoma and prostate cancer.CONCLUSIONS:The incidence of off-label indications use of carrelizumab in the hospital is relatively high,and the level of evidence-based medicine is relatively low.Therefore,the management of off-label indications use of carrelizumab should be strengthened,and off-label indications use of carrelizumab without evidence-based medicine should be restricted to ensure the medication safety of patients.

关 键 词：卡瑞利珠单抗 超适应证用药 合理用药 

分 类 号：R979.1[医药卫生—药品]